New DNA vaccine shows promise against deadly MERS virus
NCT ID NCT04588428
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested a new DNA vaccine called INO-4700 in 192 healthy adults to see if it is safe and can trigger an immune response against MERS, a serious coronavirus. The vaccine is given as a shot under the skin followed by a quick electric pulse to help cells take up the DNA. The study looked at side effects and measured antibodies and T-cell responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- INO-4700 (DNA vaccine given under the skin followed by a mild electric pulse to boost uptake)
- What this could lead to
- If successful, this could lead to a vaccine that protects people from MERS, a serious respiratory virus.
- What could go wrong
- This is a Phase 2 trial with only 192 healthy volunteers, so it is still early. The vaccine may not produce strong enough immunity or could cause side effects like injection site reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-COV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ahero Clincal Trials Unit
Kisumu, 40100, Kenya
-
American University of Beirut Medical Center
Beirut, Lebanon
-
Clinical Research Center, Irbid Specialty Hospital (CRC/ISH)
Irbid, 21110, Jordan
-
Hammoud Hospital University Medical Center
Saida, Lebanon
-
Kenya Medical Research Institute (KEMRI)/Walter Reed Project (WRP)
Kericho, 20200, Kenya
-
Pharmaceutical Research Center / Jordan University of Science and Technology
Irbid, 22110, Jordan